Avasimibe (Synonyms: Cl-1011, PD-148515)

Cell lines

HepG2 cells; rat hepatocytes; THP-1 cells

Preparation method

The solubility of this compound in DMSO is >25.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.2 μM-10 μM; 24 h

Applications

In THP-1 cells, avasimibe (0-0.2 μM) did not reduce intracellular cholesteryl ester content in a sequential incubation system. Incubations with avasimibe (0-0.2 μM) during the process of lipid loading (simultaneous incubation with avasimibe and acetyl-LDL) caused a concentration-dependent reduction in cellular cholesteryl ester content, which reached 70% at 0.2 μM. Incubation with avasimibe (10 nM - 10 μM) for 24 h caused a significant dose-dependent reduction in apo B 100 secretion from HepG2 cells. Overnight incubation of HepG2 cells with 10 μM avasimibe suppressed apo B synthesis, as well as the synthesis of other hepa-to-specific proteins. Avasimibe (3 μM) caused a 2.9-fold increase in total bile acid synthesis in rat hepatocytes.

Animal models

Rats, Mice

Dosage form

Oral; 1, 10, or 30 mg/kg/day; 2 weeks

Application

In mice, treatment with avasimibe significantly reduced the number of lesions containing accumulations of free cholesterol. In cholesterol-fed rats treated with multiple oral doses of the compound, avasimibe significantly reduced plasma total cholesterol and increased HDL-cholesterol. Avasimibe (0.01% in the diet for 1 week) reduced plasma cholesterol levels in rats fed a high fat-high cholesterol diet, supplemented or not with 0.5% cholate, by 52 to 71%. Treatment with avasimibe (3–30 mg/kg/day) for 8–10 weeks lowered plasma total cholesterol, VLDL-cholesterol, LDL-cholesterol, and triglyceride levels.In chow-fed rats, avasimibe (3–30 mg/kg) reduced plasma cholesterol levels by 44 to 66%.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Llaverías G, Laguna JC, Alegret M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). 2003 Spring;21(1):33-50.